Enterohaemorrhagic Escherichia coli – dangerous new pathogens
Authors:
Helena Ambrožová 1; Monika Marejková 2
Authors place of work:
I. infekční klinika 2. LF UK a Nemocnice Na Bulovce, Praha
1; Národní referenční laboratoř pro Escherichia coli a shigely, Státní zdravotní ústav Praha
2
Published in the journal:
Čas. Lék. čes. 2012; 151: 514-518
Category:
Review Articles
Summary
Enterohaemorrhagic Escherichia coli first described in the United States in 1983, are important, worldwide spread zoonotic pathogens with a significant outbreak potential. Besides uncomplicated diarrhoea, they can cause severe complications in children and adults including haemolytic – uremic syndrome and rarely thrombotic thrombocytopenic purpura. Haemolytic – uremic syndrome is the most frequent cause of acute renal failure in children. In this article we review present knowledge about etiology, epidemiology, clinic, treatment and prevention of these infections including new data from National Reference Laboratory for Escherichia coli and shigella in Prague about the occurrence of enterohaemorrhagic Escherichia coli in the Czech Republic.
Key words:
Shiga toxin producing Escherichia coli, enterohaemorrhagic Escherichia coli, Shiga toxin, haemolytic-uremic syndrome.
Zdroje
1. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 2(2): 123–402.
2. Bolton DJ. Verocytotoxigenic (Shiga toxin – producing) Escherichia coli: virulence factors and pathogenicity in the farm to fork paradigm. Foodborne Pathog Dis 2011; 8(3): 357–365.
3. Epidemiologic Notes and Reports. Thrombotic Thrombocytopenic Purpura Associated with Escherichia coli O157:H7-Washington. MMWR Weekly 1986; 35(34): 549–551.
4. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295: 405–418.
5. Pennington H. Escherichia coli O157. Lancet 2010; 376(23): 1428–1435.
6. Lhotová H, Bielaszewska M, Kopalová E, Štolbová M. Haemolyticko-uremický syndrom – mikrobiologické šetření. Čs. epid. microb. imunol. 1990; 39: 13–20.
7. Friedrich AW, Bielaszewska M, Zhang WL, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. The Journal of Infectious Diseases 2002; 185: 74–84.
8. Orth D, Würzner R. Complement in typical hemolytic uremic syndrome. Semin Tromb Hemost 2010; 366: 620–624.
9. Money P, Kelly AF, Gould SW, et al. Cattle, weather and water: mapping Escherichia coli O157:H7 infections in humans in England and Scotland. Environ Microbiol 2010; 12(10): 2633–2644.
10. Ferens WA, Hovde CJ. Escherichia coli O157:H7: animal reservoir and sources of human infection. Foodborne Pathog Dis 2011; 8(4): 465–487.
11. Nishikawa K. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin – producing Escherichia coli. Arch Immunol Ther Exp 2011; 59(4): 239–247.
12. Jackson MP, Neill RJ, O´Brien AD, et al. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by acteriophages from Escherichia coli 933. FEMS Microbiology letters 1987; 44(1): 109–114.
13. Tarr PI, Gordon CA, Chandler WL. Shiga toxin-producing Escherichia coli and the haemolytic uremic syndrome. Lancet 2005; 365: 1073–1086.
14. Zoja C, Buelli S, Morici M. Shiga toxin – associated hemolytic uremic syndrome: Pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010; 25(11): 2231–2240.
15. Bitzan M. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int Suppl 2009; 112: S2–6.
16. Karch H, Mellmann A, Bielaszewska M. Epidemiology aand pathogenesis of enterohaemorrhagic Escherichia coli. Berl Munch Tierarztl Wochenschr 2009; 122(11–12): 417–424.
17. Lim JY,Yoon J, Hovde C. A brief overview of Escherichia coli O157:H7 and its plastid O157. J Microbiol Biotechnol 2010; 20(1): 5–14.
18. Bielaszewska M, Sinha B, Kuczius T, Karch H. Cytolethal distending toxin from Shiga toxin-producing Escherichia coli O157 causes irreversible G2/M arrest, inhibition of proliferation, and death of human endothelial cells. Infect. Immun 2005; 73: 552–562.
19. Aldick T, Bielaszewska M (shared first authorship), Zhang W, Brockmeyer J, et al. Hemolysin from Shiga toxin-negative Escherichia coli O26 strains injures microvascular endothelium. Microbes Infect 2007; 9: 282–290.
20. Brockmeyer J, Bielaszewska M, Fruth A, et al. Subtypes of the plasmid-encoded serine protease EspP in Shiga toxin- producing Escherichia coli: Distribution, secretion, and proteolytic activity. Appl. Environ. Microbiol 2007; 73: 6351–6359.
21. Garcia A, Fox JG, Besser TE. Zoonotic enterohemorrhagic Escherichia coli: A One Heath perspective. ILAR J 2010; 51(3): 221–232.
22. Chase-Topping M, Gally D, Low C, et al. Super – shedding and the link between human infection and livestock carriage of Esherichia coli O157. Nat Rev Microbiol 2008; 6(12): 904–912.
23. La Ragione RM, Best A, Woodward MJ, et al. Escherichia coli O157:H7 colonization in small domestic ruminants. FEMS Microbiol Rev 2009; 33(2): 394–410.
24. Berger CN, Sodha ASV, Shaw RK, et al. Fresh fruit and vegetables as vehicle for the transmission of human pathogens. Environ Microbiol 2010; 12(9): 2385–2397.
25. Franz E, van Bruggen AH. Ecology of E. coli 0157:H7 and Salmonella enterica in the primary vegetable production Chin. Crit Rev Microbiol 2008; 34(3–4): 143–161.
26. Matsell DG, White CT. An outbreak of diarrhoea – associated childhood hemolytic uremic syndrome: the Walkerton epidemic. Kidney Int Suppl 2009; 112: S35–37.
27. Wendel AM, Johnson DH, Sharapov U, et al. Multistate Outbreak of Escherichia coli O157:H7 Infection Associated with Consumption of Packaged Spinach, August September 2006: The Wisconsin Investigation. CID 2009; 48: 1079–1086.
28. Watanabe Y, Ozasa K, Mermin JH, et al. Factory Outbreak of Escherichia coli O157:H7 Infection in Japan. Emerg Infect Dis 1999; 5(3): 424–428.
29. Malina M, Roumenina LT, Seeman T, et al. Genetics of hemolytic uremic syndromes. Presse Med 2012; 41(3): 105–114.
30. Marejková M, Roháčová H, Reisingerová M, Petráš P. An imported case of hemorrhagic colitis in Czech Republic caused by a Shiga toxin-producing Escherichia coli O104:H4 strain associated with the large German outbreak, May 2011 Folia Microbiol 2012; published on-line 19 January 2012; doi 10.1007/s12223-011-0095-0
31. Beutin L, Martin A. Outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infection in Germany causes a paradigm shift with regard to human pathogenicity of STEC strains. J Food Prot 2012; 75(2): 408–418.
32. Bielaszewska M, Mellmann A, Zhang W, et al. Characterization of the Escherichia coli strain associated with an outbreak of hemolytic uremic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 11; (9): 671–676.
33. Karmali MA. Host and pathogen determinants of verocytotoxin – producing Escherichia coli – associated hemolytic uremic syndrome. Kidney Int Suippl 2009; 112: S4–7
34. Marejková M, Zieg J, Dušek J, et al. Smrtelný případ diareapozitivního hemolyticko – uremického syndromu vyvolaného enterohemoragickým kmenem Escherichia coli O26. Zprávy epidemiologie a mikrobiologie 2009; 18(6): 212–214.
35. Bielaszewska M, Janda J. Mikrobiologické aspekty infekce kmeny E. coli produkujícími verotoxin u dětí s hemolyticko-uremickým syndromem. Epid mikrob imunol 1989; 38: 237–244.
36. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of Haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1: 619–620.
37. Bielaszewska M, Janda J, Bláhová K, et al. Human Escherichia coli O157:H7 infection associated with the consumption of unpasteurized goat’s milk. Epidemiol Infect 1997; 119: 299–305.
38. Friedrich AW, Bielaszewska M, Zhang WL, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185: 74–84.
39. Bielaszewska M., Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 2006; 43: 1160–1167.
40. Suri RS, Mahon JL, Clark WF, et al. Relationship between Eschrichia coli O157:H7 and diabetes mellitus. Kidney Int Suppl 2009; 112: S44–46.
41. Müthing J, Schweppe CH, Karch H, et al. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Tromb Haemost 2009; 101(2): 252–264.
42. Tarr PI. Shiga toxin- associated hemolytic učenic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms and pathogenesis. Kidney Int Suppl 2009; 112: S29–32.
43. Werber D, Behnke SC, Fruth A, et al. Shiga toxin-producing Escherichia coli infection in Germany: different risk factors for different age groups. Am J Epidemiol 2007; 165: 425–434.
44. Serna A 4th, Boedeker EC. Pathogenesis and treatment of Shiga toxin – producing Escherichia coli infections. Curr Opin Gastroenterol 2008; 24(1): 38–47.
45. Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: Association with intravenous volume expansion. Pediatrics 2005; 115: 673–680.
46. Palermo MS, Exeni RA, Fernández GC. Hemolytic-uremic syndrome: pathogenesis and update of interventions. Expert Rev Anti Infect Ter 2009; 7(6): 697–707.
47. Zieg J, Bláhová K, Dušek J, et al. Hemolyticko – uremický syndrom. Pediatrie pro praxi 2011; 12(2): 102–104.
48. Khanna R, Waechter L, Sargeant J, et al. Environmental prevention of human disease from verocytotoxin – producing Escherichia coli. Nephrol Dial Transplant 2008; 23(6): 1819–1822.
49. Malina M, Janda J, Seeman T. Hemolyticko-uremický syndrom – nejčastější příčina akutního renálního selhání u dětí. Komplexnost patofyziologie a nové možnosti diagnostiky a terapie atypických forem. Čsl. Pediatrie 2010; 65(11): 648–653.
50. Rosales A, Hofer J, Zimmerhackl LB, et al. Need for long- term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54(10): 1413–1421.
51. Moist LM, Sontrop JM, Garg AX. Risk of preghnancy-related hypertension within five years of exposure to bacteria- contaminated drinking water. Kidney Int Suppl 2009; 112: S47–49.
52. Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36(6): 594–610.
53. Wegener HC. Danish initiatives to improve the safety of meat products. Meat Sci 2010; 84(2); 273–283.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Papilledema and ischemic edema of the optic nerve head
- Enterohaemorrhagic Escherichia coli – dangerous new pathogens
- Lymphogranuloma venereum
- Principles of dealing with human DNA and genotyping information